Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2005 Dec;26(6):463-72.
doi: 10.1016/j.ijantimicag.2005.08.016. Epub 2005 Nov 8.

Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan

Affiliations
Comparative Study

Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan

Po-Ren Hsueh et al. Int J Antimicrob Agents. 2005 Dec.

Abstract

This study was conducted to evaluate the relationship between antimicrobial resistance and antimicrobial use in a university hospital in Taiwan. Disk susceptibility data of Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus spp., Pseudomonas aeruginosa, Acinetobacter spp., Stenotrophomonas maltophilia and other non-fermentative Gram-negative bacilli causing nosocomial infections were evaluated. Data on annual patient-days and annual consumption (defined daily dose (DDD) per 1000 patient-days) of extended-spectrum cephalosporins (cefotaxime, ceftriaxone, ceftazidime, flumoxef, cefepime and cefpirome), beta-lactam-beta-lactamase inhibitor combinations (ticarcillin/clavulanic acid and piperacillin/tazobactam), carbapenems (imipenem and meropenem), aminoglycosides (amikacin, gentamicin and tobramycin), fluoroquinolones (ciprofloxacin (oral and injectable) and oral levofloxacin and moxifloxacin) from 1991 to 2003 were analysed. Increasing trends of incidences of several of these bacteria causing all nosocomial infections or nosocomial bloodstream infections were noted from 1991 to 2003. The annual patient-days of the hospital significantly increased, from 360210 in 1991 to 672676 in 2002 (linear regression analysis, P < 0.05), but slightly decreased in 2003 (629168) owing to the severe acute respiratory syndrome epidemic in Taiwan. The rise in cefotaxime-resistant or ciprofloxacin-resistant E. coli and meropenem-resistant P. aeruginosa was significantly correlated with increased consumption of extended-spectrum cephalosporins, beta-lactam-beta-lactamase inhibitor combinations, carbapenems, fluoroquinolones and aminoglycosides (for ciprofloxacin-resistant E. coli and meropenem-resistant P. aeruginosa only) in the hospital (Pearson's correlation coefficient, r > 0.72 (or < -0.72) and P-value < 0.05). Increased ciprofloxacin-resistant K. pneumoniae and meropenem-resistant Acinetobacter spp. was significantly associated with the increased usage of extended-spectrum cephalosporins but not with the other four classes of antibiotics. This 13-year study in a hospital demonstrated significant changes in antimicrobial use, which may have affected antimicrobial resistance in certain Gram-negative bacteria at the hospital.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Incidence (episodes per 10 000 discharged) of (A) all nosocomial infections and (B) nosocomial bloodstream infections caused by major Gram-negative bacilli isolated from patients treated at a university hospital in Taiwan from 1991–2003. NFGNB, non-fermentative Gram-negative bacilli.
Fig. 2
Fig. 2
(A) Annual patient-days and (B) annual consumption (defined daily dose (DDD) per 1000 patient-days) of five classes of antimicrobial agents and resistance trends for five drug/organism combinations at a university hospital in Taiwan from 1991–2003.
Fig. 3
Fig. 3
Yearly percentage of (A) cefotaxime-resistant Escherichia coli and (B) ceftazidime-resistant Pseudomonas aeruginosa observed between 1991 and 2003 and predicted values up to 2011 with 95% confidence intervals according to autoregressive integrated moving average (ARIMA) and transfer function models.

Similar articles

Cited by

References

    1. Archibald L., Phillips L., Monnet D. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis. 1997;24:211–215. - PubMed
    1. Flamm R.K., Weaver M.K., Thornsberry C. Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob Agents Chemother. 2004;48:2431–2436. - PMC - PubMed
    1. Rhomberg P.R., Jones R.N., Sader H.S. Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres. Int J Antimicrob Agents. 2004;23:52–59. - PubMed
    1. Sader H.S., Biedenbach D.J., Jones R.N. Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48, 440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997–2001) Diagn Microbiol Infect Dis. 2003;47:361–364. - PubMed
    1. Fridkin S.K., Steward C.D., Edwards J.R. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis. 1999;29:245–252. - PubMed

Publication types

MeSH terms